Smart pills are small embedded electronic devices, which include sensors, cameras, patches and trackers. These electronic devices can easily be swallowed and it provides complete evaluation of the gastrointestinal tract.
The global ingestible smart pills market is estimated to account for US$ 1,175.4 Mn in terms of value and is expected to reach US$ 1,734.3 Mn by the end of 2027.
Global Ingestible Smart Pills Market: Drivers
Increasing prevalence of gastrointestinal diseases is expected to propel growth of the global ingestible smart pills market over the forecast period. For instance, according to the study, ‘Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies’, published in the journal Lancet in 2018, the prevalence of Crohn's disease in Germany was 22 per 100,000 and 319 per 100,000 in Canada.
Moreover, several benefits of ingestible smart pills are also expected to aid in growth of the market. For instance, according to a paper in the November 2019 issue of the Journal of Managed Care & Specialty Pharmacy, AdhereTech’s smart pill bottle platform improved adherence and patient satisfaction among a small sample of multiple myeloma patients.
Statistics:
Smart pills held dominant position in the global ingestible smart pills market in 2019, accounting for 81.7% share in terms of value, followed by workstation, respectively.
Figure 1. Global Ingestible Smart Pills Market Share (%), by Value, by Treatment Type, 2019
To learn more about this report, Request sample copy
Global Ingestible Smart Pills Market: Restraints
Several players in the market are failing to attract investors, which is expected to hinder growth of the global ingestible smart pills market. For instance, in June 2020, Proteus Digital Health, Inc. filed for bankruptcy protection. In 2019, Proteus Digital Health, Inc. faced cash crunch and the company furloughed the majority of its employees for about two weeks in November 2019.
Moreover, high costs involved in R&D of ingestible smart pills is also expected to limit the market growth. The ingestible smart pills market is multidisciplinary and requires domain experts from various disciplines of science such as biochemists, biologists, microbiologists, immunologists, medical scientists and electronic engineers. It requires a consolidated effort between all these varied disciplines to develop sensors for particular applications. Additionally, prolonged R&D timelines with the inclusion of clinical trials required to test these sensor-embedded device adds up to significant expenditure.
Ingestible Smart Pills Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2019 | Market Size in 2019: | US$ 1,111.8 Mn |
Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: | 5.7% | 2027 Value Projection: | US$ 1,734.3 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
BodyCap Medical, Given Imaging Ltd., Olympus Corporation, Proteus Digital Health, Inc., CapsoVision, Inc., Chongqing Jinshan Science and Component (Group) Co., Ltd., Medimetrics, IntroMedic Co., Ltd., Check-Cap Ltd., Boston Scientific Corporation, HQ Inc., Smart Pill Inc., Medtronic plc, Philips Healthcare, etectRx, Inc., Novartis, Siemens Healthcare, Pentax Medical Company (HOYA Corporation), GE Healthcare, and Stryker Corporation. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Ingestible Smart Pills Market: Opportunities
The Covid-19 outbreak is expected to boost demand for digital medicine, thereby offering lucrative growth opportunities for players in the global ingestible smart pills market. For instance, in May 2020, Proteus Digital Health, Inc. announced a multi-year, outcomes-based initiative with the state of Tennessee’s Medicaid program, TennCare, in order to support TennCare-covered patients undergoing Hepatitis C treatment to achieve a cure through improved medication adherence and stronger connections to their care teams.
Moreover, increasing prevalence of chronic disorders is expected to boost demand for ingestible smart pills market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
The global ingestible smart pills market was valued at US$ 1,111.8 Mn in 2019 and is forecast to reach a value of US$ 1,734.3 Mn by 2027 at a CAGR of 5.7% between 2020 and 2027.
Figure 2. Global Ingestible Smart Pills Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
To learn more about this report, Request sample copy
Market Trends/Key Takeaways
High prevalence for needle fear is expected to propel growth of the global ingestible smart pills market over the forecast period. For instance, according to the study, ‘The fear of needles: A systematic review and meta-analysis,’ published in the Journal of Advanced Nursing in January 2019, the prevalence for needle fear ranged from 20-50% in adolescents and 20-30% in young adults.
Major players in the global ingestible smart pills market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in July 2020, HOYA Corporation and Hitachi, Ltd. announced a five year contract regarding Endoscopic Ultrasound Systems by which Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor related parts used in Endoscopic Ultrasound Systems.
Global Ingestible Smart Pills Market: Competitive Landscape
Major players operating in the global ingestible smart pills market include, BodyCap Medical, Given Imaging Ltd., Olympus Corporation, Proteus Digital Health, Inc., CapsoVision, Inc., Chongqing Jinshan Science and Component (Group) Co., Ltd., Medimetrics, IntroMedic Co., Ltd., Check-Cap Ltd., Boston Scientific Corporation, HQ Inc., Smart Pill Inc., Medtronic plc, Philips Healthcare, etectRx, Inc., Novartis, Siemens Healthcare, Pentax Medical Company (HOYA Corporation), GE Healthcare, and Stryker Corporation.
Global Ingestible Smart Pills Market: Key Developments
Major players in the global ingestible smart pills market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2019, etectRx, Inc. received the U.S. Food and Drug Administration (FDA) approval for its breakthrough patented ingestible event marker, the ID-Cap System.
Share
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients